BiotechTube

exatecan mesylate

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Liver Cancer

Conditions

Liver Cancer

Trial Timeline

Sep 1, 1999 → Apr 1, 2005

NCT ID
NCT00004108

About exatecan mesylate

exatecan mesylate is a phase 2 stage product being developed by Daiichi Sankyo for Liver Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00004108. Target conditions include Liver Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Liver Cancer were approved

Approved (20) Terminated (3) Active (0)
✅Advagraf + Prograf + PrografAstellas PharmaApproved
✅Prograf + AdvagrafAstellas PharmaApproved
✅ADVAGRAF®Astellas PharmaApproved
✅Tacrolimus granules + Tacrolimus granulesAstellas PharmaApproved
✅Advagraf + PrografAstellas PharmaApproved
✅ADVAGRAF®Astellas PharmaApproved
✅tacrolimus + mycophenolate mofetil + PrednisoneAstellas PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (11)

NCT IDPhaseStatus
NCT00055952Phase 2Completed
NCT00055939Phase 2Completed
NCT00017212Phase 2Completed
NCT00005938Phase 2Completed
NCT00004866Phase 2Completed
NCT00004108Phase 2Completed
NCT00004060Phase 2Completed
NCT00004046Phase 2Completed
NCT00003951Phase 2Completed
NCT00004045Phase 2Completed
NCT00004047Phase 1Completed

Competing Products

20 competing products in Liver Cancer

See all competitors
ProductCompanyStageHype Score
LanifibranorInventivaPhase 2
29
GODEX + PlaceboCelltrionPhase 3
47
peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirinChugai PharmaceuticalPhase 3
40
TacrolimusAstellas PharmaPre-clinical
26
ATG (Fresenius Biotech)Astellas PharmaPhase 2
27
Advagraf + Prograf + PrografAstellas PharmaApproved
43
Prograf + AdvagrafAstellas PharmaApproved
43
ADVAGRAF®Astellas PharmaApproved
43
Prograf + MR4Astellas PharmaPhase 3
40
tacrolimus modified release (MR) + tacrolimusAstellas PharmaPhase 2
35
tacrolimus modified release (MR) + tacrolimusAstellas PharmaPhase 2
35
tacrolimusAstellas PharmaPhase 3
40
Prograf-XL + Prograf + MMFAstellas PharmaPhase 3
40
micafungin + fluconazole + liposomal amphotericin B + caspofunginAstellas PharmaPhase 3
40
Tacrolimus granules + Tacrolimus granulesAstellas PharmaApproved
43
FK506E (modified release tacrolimus) + Prograf (tacrolimus)Astellas PharmaPhase 3
40
FK778Astellas PharmaPhase 2
35
Tacrolimus modified-release + PrografAstellas PharmaPhase 3
40
Advagraf + PrografAstellas PharmaApproved
39
Prograf + FK506MR capsuleAstellas PharmaPhase 3
40